doi: 10.1093/jnci/djk122.
Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials
- PMID: 17341725
- DOI: 10.1093/jnci/djk122
Item in Clipboard
Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials
J Natl Cancer Inst.
.
No abstract available
Similar articles
-
Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.Nat Clin Pract Oncol. 2008 Sep;5(9):512-20. doi: 10.1038/ncponc1156. Epub 2008 Jul 1. Nat Clin Pract Oncol. 2008. PMID: 18594499 Review.
-
Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.Cancer Treat Res. 2009;151:197-215. doi: 10.1007/978-0-387-75115-3_13. Cancer Treat Res. 2009. PMID: 19593514 Review. No abstract available.
-
Lapatinib in breast cancer: clinical experiences and future perspectives.Cancer Treat Rev. 2010 Nov;36 Suppl 3:S72-9. doi: 10.1016/S0305-7372(10)70024-4. Cancer Treat Rev. 2010. PMID: 21129615 Review.
-
Cancer stem cell hypothesis and trastuzumab in HER2-negative tumors.J Natl Cancer Inst. 2012 Jul 3;104(13):968-9. doi: 10.1093/jnci/djs307. Epub 2012 Jun 28. J Natl Cancer Inst. 2012. PMID: 22745473 No abstract available.
-
An overview of HER-targeted therapy with lapatinib in breast cancer.Adv Ther. 2009 Mar;26(3):263-71. doi: 10.1007/s12325-009-0012-y. Epub 2009 Mar 27. Adv Ther. 2009. PMID: 19365626 Review.
Cited by
-
Clinical activities of the epidermal growth factor receptor family inhibitors in breast cancer.Biologics. 2007 Sep;1(3):229-39. Biologics. 2007. PMID: 19707333 Free PMC article.
-
Lapatinib: a sword with two edges.Pathol Oncol Res. 2008 Mar;14(1):1-8. doi: 10.1007/s12253-008-9018-z. Epub 2008 Apr 12. Pathol Oncol Res. 2008. PMID: 18409020 Review.
-
Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel.Wien Klin Wochenschr. 2010 Jun;122(11-12):368-79. doi: 10.1007/s00508-010-1373-6. Epub 2010 Jun 15. Wien Klin Wochenschr. 2010. PMID: 20549373
-
An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity.Clin Cancer Res. 2010 Mar 1;16(5):1466-77. doi: 10.1158/1078-0432.CCR-09-2549. Epub 2010 Feb 23. Clin Cancer Res. 2010. PMID: 20179231 Free PMC article.
-
Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.Oncotarget. 2017 Apr 25;8(17):28971-28989. doi: 10.18632/oncotarget.15952. Oncotarget. 2017. PMID: 28423644 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
